SCHEMBL7876854

SCHEMBL7876854

NC(=O)NC[C@H](N)C(=O)Nc1nccs1

nearest known ligand 0.54

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.50
HSPA5 P11021 6/20 0.49
HSPA9 P38646 3/20 0.47
HSPA2 P54652 2/20 0.46
FFAR2 O15552 2/20 0.45
LMNA P02545 2/20 0.45
XBP1 P17861 1/20 0.45
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2D6 P10635 1/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
TSHR P16473 1/20 0.45
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45
ACP1 P24666 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7868150 0.87 ALDH1A1 (0.51) SMN1; SMN2HSPA5HSPA9HSPA2FFAR2
SCHEMBL9072828 0.82 HSPA5 (0.49) SMN1; SMN2HSPA5HSPA9FFAR2LMNA
SCHEMBL7868117 0.80 NPC1 (0.66) SMN1; SMN2HSPA5HSPA9HSPA2LMNA
SCHEMBL27228868 0.78 FFAR2 (0.60) SMN1; SMN2HSPA5HSPA9HSPA2FFAR2
SCHEMBL5875678 0.78 CYP1A2 (0.62) SMN1; SMN2HSPA5HSPA2FFAR2LMNA
SCHEMBL7873351 0.78 FFAR2 (0.60) SMN1; SMN2HSPA5HSPA9HSPA2FFAR2
SCHEMBL352731 0.76
Hydrochloric Acid SCHEMBL17186333 0.74 NPC1 (0.56) SMN1; SMN2LMNANPC1RAB9AACP1
Bromide SCHEMBL11317007 0.74 LMNA (0.57) HSPA5HSPA9HSPA2FFAR2LMNA
SCHEMBL2672708 0.73 EPHX2 (0.60) FFAR2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6329400-B1 INHIBITION OR ANTAGONISM OF MATRIX METALLOPROTEASES, AND/OR TUMOR NECROSIS FACTOR-ALPHA; EXTRACELLULAR MATRIX DEGRADATION, INHIBITION OF SHEDDING OF CELL SURFACE PROTEIN ECTODOMAINS AND CD23 PROTEOLYSIS GLAXO WELLCOME INC. 2001-12-11 US disclosed